Résumé
Rendu-Osler disease (ROD), also known as hereditary hemorrhagic telangiectasia (HHT), is arare vascular genopathy (1/5000 cases) affecting multiple organs. The mutation of a gene (ENG, ACVRL1 or MADH4) causes an imbalance between pro-angiogenic and anti-angiogenic factors, resulting in the absence of angiogenesis quiescence in adults. The result is vascular abnormalities leading to epistaxis, telangiectasia of the skin and digestive mucosa, and AVMs in the liver, lungs and brain. Given this pathophysiology, an anti-angiogenic (oranti-VEGF) treatment such as Bevacizumab (avastin®) would appear to be of interest. The granting of an ATU/AMM for bevacizumab, thanks to a national data collection system (CIROCO), should make it possible to carry out new studies at international level or with other anti-VEGF agents.